Bousquet J, Hejjaoui A, Clauzel A M, Guérin B, Dhivert H, Skassa-Brociek W, Michel F B
Clinique des Maladies Respiratoires, Centre Hospitalier Universitaire, Montpellier, France.
J Allergy Clin Immunol. 1988 Dec;82(6):971-7. doi: 10.1016/0091-6749(88)90133-9.
House dust mites of the species Dermatophagoides pteronyssinus (Dpt) represent one of the major allergens inducing asthma. However, a strict allergy to Dpt is not always observed in Dpt-allergic patients, since nonallergic and other allergic triggering factors often coexist. It was suggested that specific immunotherapy with house dust-mite extracts is more effective in children than in adults. A controlled study was undertaken in 215 Dpt-allergic patients with asthma ranging in age from 3 to 72 years (mean +/- SD, 28.2 +/- 10.9 years) to investigate parameters that might predict the efficacy of specific immunotherapy before it is started; 171 patients received a rush immunotherapy protocol with a standardized Dpt extract and, subsequently, maintenance injections with 3000 BU of this extract, and 44 patients served as a control group. Before immunotherapy, all patients had a complete evaluation of the severity of asthma by symptom-medication scores and a pulmonary function test, as well as a study of other triggering factors by checking on seasonal and perennial allergens, sinusitis, and other possible causes, such as aspirin intolerance; 196 patients were investigated between 9 and 12 months after the onset of the survey by means of pulmonary function tests and symptom-medication scores. Medications were adapted according to peak flow rates. It was observed that patients with chronic sinusitis, and/or aspirin intolerance, and/or other perennial allergies did not benefit from specific immunotherapy; therefore, the treatment of a major etiologic factor did not demonstrate improvement in the patients.(ABSTRACT TRUNCATED AT 250 WORDS)
屋尘螨中的粉尘螨是诱发哮喘的主要变应原之一。然而,在粉尘螨过敏患者中并非总能观察到对粉尘螨的严格过敏反应,因为非过敏和其他过敏触发因素常常并存。有人提出,用屋尘螨提取物进行特异性免疫疗法对儿童的效果比对成人更好。对215名年龄在3至72岁(平均±标准差,28.2±10.9岁)的粉尘螨过敏哮喘患者进行了一项对照研究,以调查在开始特异性免疫疗法之前可能预测其疗效的参数;171名患者接受了标准化粉尘螨提取物的快速免疫疗法方案,随后用3000 BU的该提取物进行维持注射,44名患者作为对照组。在免疫疗法之前,所有患者都通过症状 - 用药评分和肺功能测试对哮喘严重程度进行了全面评估,还通过检查季节性和常年性变应原、鼻窦炎以及其他可能原因(如阿司匹林不耐受)对其他触发因素进行了研究;196名患者在调查开始后9至12个月通过肺功能测试和症状 - 用药评分进行了调查。药物根据峰值流速进行调整。观察到患有慢性鼻窦炎、和/或阿司匹林不耐受、和/或其他常年性过敏的患者并未从特异性免疫疗法中获益;因此,治疗主要病因因素并未使患者病情得到改善。(摘要截选至250字)